Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kedrion and ProMetic Life have signed a definitive agreement for development of two hyperimmunes.
Subscribe to our email newsletter
The first product to be developed will target the hepatitis B hyperimmune. Kedrion has in-licensed ProMetic’s technologies for the manufacturing of hyperimmune products in Europe. Royalties, licensing and service fees for the sales of products in Europe will be paid by Kedrion to ProMetic with ProMetic retaining the commercial rights for the fully developed hyperimmune products for the North American market. ProMetic will in turn pay Kedrion royalties on its sales of the hyperimmune products in North America.
The product development program, including the clinical trial designed to meet US and European regulatory requirements, will be funded by Kedrion. Full scale commercial manufacturing will take place in Kedrion’s facility in Italy. Kedrion will be the holder of the products registration for both markets.
Pierre Laurin, president and CEO of ProMetic, said: “This agreement with Kedrion will leverage ProMetic’s ability to penetrate into the North American hyperimmune product market and expand on our existing revenue base.”